Editorials

1201 Hyperkalemia in Predialysis Patients
Biff F. Palmer
See related article on page 1234.

1203 Is Long-Term Prediction in Membranous Nephropathy (MGN) Better Than the Weatherman’s Forecast Capacity?
Daniel C. Cattran and Joseph Kim
See related article on page 1242.

1206 Getting Excited about Exit Sites in Peritoneal Dialysis?
Peter G. Blake
See related article on page 1266.

1209 Sequestration and Suppression of Anti-HLA Antibodies by a Failed Kidney Allograft
Vinay Nair and Peter S. Heeger
See related article on page 1310.

Original Articles

Acid/Base and Electrolyte Disorders
1211 Does the Exposure of Urine Samples to Air Affect Diagnostic Tests for Urine Acidification?
Joo-Hark Yi, Hyun-Jong Shin, Sun-Moon Kim, Sang-Woong Han, Ho-Jung Kim, and Man-Seok Oh

Acute Kidney Injury /Acute Renal Failure
1217 FGF-23 Levels in Patients with AKI and Risk of Adverse Outcomes
David E. Leaf, Myles Wolf, Sushrut S. Waikar, Herbert Chase, Marta Christov, Serge Cremers, and Leonard Stern

1224 Association between Peritransplant Kidney Injury Biomarkers and 1-Year Allograft Outcomes
Isaac E. Hall, Mona D. Doshi, Peter P. Reese, Richard J. Marcus, Heather Thiessen-Philbrook, and Chirag R. Parikh

Clinical Nephrology
1234 Prevalence and Factors Associated with Hyperkalemia in Predialysis Patients Followed in a Low-Clearance Clinic
Pantelis A. Sarafidis, Rochelle Blacklock, Eleri Wood, Adam Rumjon, Shanique Simmonds, Jessica Fletcher-Rogers, Rachel Ariyanayagam, Aziza Al-Yassin, Claire Sharpe, and Katie Vinen
See related editorial on page 1201.

1242 Prognostic Value of Risk Score and Urinary Markers in Idiopathic Membranous Nephropathy
Jan A.J.G. van den Brand, Julia M. Hofstra, and Jack F.M. Wetzels
See related editorial on page 1203.

Clinical Pharmacology
1249 Pharmacokinetics of Intraperitoneal Gentamicin in Peritoneal Dialysis Patients with Peritonitis (GIPD Study)
Julie M. Varghese, Jason A. Roberts, Steven C. Wallis, Robert J. Boots, Helen Healy, Robert G. Fassett, Jeffrey Lipman, and Dwarakanathan Ranganathan
ESRD and Chronic Dialysis

1257 Decoy Receptor 3, a Novel Inflammatory Marker, and Mortality in Hemodialysis Patients
Szu-Chun Hung, Ta-Wei Hsu, Yao-Ping Lin, and Der-Cherng Tarng

1266 The Association between Exit Site Infection and Subsequent Peritonitis among Peritoneal Dialysis Patients
Anouk T.N. van Diepen, George A. Tomlinson, and Sarbjit V. Jassal
See related editorial on page 1206.

1272 Serum Potassium and Cause-Specific Mortality in a Large Peritoneal Dialysis Cohort
Klara Torlén, Kamyar Kalantar-Zadeh, Miklos Z. Molnar, Tania Vashistha, and Rajnish Mehrotra

1285 Troponin T for the Detection of Dialysis-Induced Myocardial Stunning in Hemodialysis Patients
Tobias Breidthardt, James O. Burton, Aghogho Odudu, Mohamed Tarek Eldehni, Helen J. Jefferies, and Christopher W. McIntyre

Genetics

1293 Association of HLA Genes with Clinical Outcomes of ANCA-Associated Vasculitis
Dong-yuan Chang, Huan Luo, Xu-jie Zhou, Min Chen, and Ming-Hui Zhao

Hypertension

1300 Probing the Mechanisms of Intradialytic Hypertension: A Pilot Study Targeting Endothelial Cell Dysfunction
Jula K. Inrig, Peter Van Buren, Catherine Kim, Wanpen Vongpatanasin, Thomas J. Povsic, and Robert Toto

Renal Transplantation

1310 Donor-Specific Antibodies after Ceasing Immunosuppressive Therapy, with or without an Allograft Nephrectomy
Arnaud Del Bello, Nicolas Congy-Jolivet, Federico Sallusto, Celine Guilbeau-Frugier, Isabelle Cardeau-Desangles, Marylise Fort, Laure Esposito, Joelle Guitard, Olivier Cointault, Laurence Lavayssière, Marie Béatrice Nogier, Antoine Blancher, Lionel Rostaing, and Nassim Kamar
See related editorial on page 1209.

1320 Incidence and Outcomes of BK Virus Allograft Nephropathy among ABO- and HLA-Incompatible Kidney Transplant Recipients
Adnan Sharif, Nada Alachkar, Serena Bagnasco, Duvuru Geetha, Gaurav Gupta, Karl Womer, Lois Arend, Lorraine Racusen, Robert Montgomery, and Edward Kraus

In-Depth Review

1328 Renal Replacement Therapy in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation
David J. Askenazi, David T. Selewski, Matthew L. Paden, David S. Cooper, Brian C. Bridges, Michael Zappitelli, and Geoffrey M. Fleming

Mini-Review

1337 Transthyretin Amyloidosis and the Kidney
Luısa Lobato and Ana Rocha

Special Features

1347 Nephrology Quiz and Questionnaire: Renal Replacement Therapy
Thomas A. Golper (Discussant), Richard J. Glassock (Co-Moderator), and Anthony J. Bleyer (Co-Moderator)

1353 A Tribute to George E. Schreiner
Robert J. Rubin
Paul D. Doolan
**On the Cover**

What’s the diagnosis? Nodular glomerulopathy is a lesion classically seen in patients with diabetic renal disease. Similar pattern of glomerular injury may also be seen in heavy smokers and patients with light and/or heavy chain deposition disease. The mechanism of injury in these circumstances is probably similar, where glucose, cigarette smoke components, or paraproteins cause toxic injury of mesangial cells, and they in turn overproduce the mesangial matrix with formation of nodules. Long-standing membranoproliferative glomerulonephritis (MPGN) can also result in prominent mesangial expansion and nodular glomerulopathy; PAS or silver stains usually show well-developed double contours of the peripheral capillary loops in such cases. Healed mesangiolytic lesions in the context of thrombotic microangiopathy can also result in segmental nodular glomerulosclerosis. Immunofluorescence and electron microscopy studies, as well as detailed clinical history, are essential in differentiating these conditions and diseases. (Image and text provided by Vanesa Bijol, MD, Brigham and Women’s Hospital)